UNSPSC 51272705: Dyclonine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C18H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZEC193879Q, chemically known as 1-propanone, 1- (4-butoxyphenyl)-3-(1-piperidinyl)-, hydrochloride but more generally known as dyclonine hydrochloride, which bears US NIH Compound Identifier 3180. European Medicines Agency schedules Dyclonine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01848MIG.

Most nations, for tariff and trade purposes, schedule dyclonine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DYCLONINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dyclonine hydrochloride bears US NLM identifiers UMLS ID C0304455 and NCI Concept Code C66875. SMILES: CCCCOC1CCC(CC1)C(=O)CCN2CCCCC2.CL.

UNSPSC 51272705 Dyclonine hydrochloride is a Commodity code that nominally covers a local-anesthetic pharmaceutical ingredient, but recent state and local procurement activity under this code shows minimal direct relevance to dyclonine itself. The three recent opportunities posted between January and June 2026 involve naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic-pharmacy direct-to-manufacturer initiative (Texas HHS), and generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations directly name dyclonine or reference the pharmaceutical ingredient specified in the code name. The issuing bodies include county health systems, state health-services agencies, and cooperative purchasing alliances spanning Florida, Texas, Minnesota, and Oregon. The mismatch between the code's nominal scope and the actual work being bought suggests this code may be used inconsistently or that dyclonine procurement does not drive substantial state and local volume.

Recent activity shows pharmaceutical procurement concentrated in three distinct operational models: direct product acquisition (Seminole County's IFB for naloxone and drug-deactivation systems with quarterly deliveries by July 26, 2023), market-intelligence gathering (Texas HHS's RFI posted April 3, 2026, exploring direct-to-manufacturer contracting models prior to formal RFP issuance), and cooperative multi-state sourcing (MMCAP's RFP issued January 20, 2026, establishing multi-award contracts for generic pharmaceuticals effective July 1, 2026, with proposals due March 26, 2026). The MMCAP procurement is the largest in operational scope, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), certify cGMP and Drug Supply Chain Security Act compliance, carry $5,000,000 commercial general liability insurance, and accept a 3 percent administrative fee on contract purchases. None of the three opportunities specify set-aside designations or disadvantaged-enterprise restrictions. Bidders on the Seminole County IFB must comply with E-Verify requirements and drug-free workplace certification; the county contract carries a three-month probationary termination clause and potential FEMA funding with attendant federal environmental compliance obligations. Because the code shows no direct dyclonine solicitations and the recent opportunities address broader pharmaceutical categories, activity under this code warrants close monitoring rather than immediate pursuit.